Total labs
30
Total footprint
30,000 sq ft
Set to open in 2026, OMX will offer the much-needed lab space needed to scale growing Deep Tech companies — and it will do so within the supportive, well-connected ecosystem built by Science Creates.
Join our community of scientific entrepreneurs developing technologies that include groundbreaking cancer treatments, enhanced battery technologies and seaweed-based biomaterials.
Located in the heart of Bristol and connected to our Old Market incubator, OMX is designed with the specialised services and features that Deep Tech R&D demands, plus the flexibility that growing ventures need.
With 30,000 sq ft of lab, office and meeting space, OMX offers a range of options depending on the size of your company — from lab-only options to full suites including two labs and a private office.
Membership includes access to our platform of support, providing opportunities to attend workshops and events, connect with other founders, and find a mentor.
Express your interest to secure a space at our newest Bristol incubator.
Travel between locations is measured in walking distance
St Philips Rd & Midland Rd
0.5 miles / 11 min
0.7 miles / 15 min
Lifecare is committed to improving the lives of people and pets with diabetes. It is developing the next-generation of miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers to the market. The company’s spin-off entity Lifecare Chemistry Ltd was founded to enhance research collaboration and secure ownership of its improved analyte-specific chemical receptor developments.
EnsiliTech is improving the shelf-life and global accessibility of vaccines and other biological therapeutics by combatting cold chain transport and storage issues. Its novel ensilication technology, designed for both existing and new biopharmaceutical formulations, encases thermally unstable biomolecules within silica nanoshells to prevent environmental degradation. This eliminates the need for cold chain requirements that are expensive, prone to failure and generate significant carbon dioxide emissions.
Reach Industries is optimising lab and scientist efficiency with its Lumi™ visual intelligence platform. By automating data capture and analysis for experiments, observations and complex scientific workflows, the platform functions as a streamlined operating system that is accelerating R&D, improving compliance and increasing reproducibility.
Fine Agrochemicals is enhancing crop quality for fruit and flower growers in agricultural, ornamental and landscape markets using its plant growth regulator (PGR) technology. Its PGR products, made using naturally occurring molecules through fermentation and combined with chemically synthesised compounds, help stimulate plant cells to enhance nutrient levels and targeted growth for improved crop outputs.
QLM Technology is developing advanced quantum lidar camera technology to identify greenhouse gas emissions. With continuous monitoring, cost-effective and 3D accuracy capabilities, it offers an effective and scalable solution to pinpointing leaks of the world’s largest emitters, like methane, within the oil and gas industry.
Argonaute RNA is developing safe, reliable and targeted methods of temporarily silencing genes in different tissue cells. It does this via the proprietary modification of small interfering RNA (siRNA), using a novel stabilisation method to overcome previous obstacles to developing siRNA drugs for healthcare.
Extracellular is developing cell culture technologies to use the cell samples of living animals and plants to create sustainable alternatives to commercial products in the cosmetic, material and food industries. As a bioprocessing and manufacturing partner, it provides solutions from cell-line and scale-up development to facilitating routes to market, supporting other biotech companies seeking to develop greener consumer products such as cultivated meat, dairy products, leather, cotton and active ingredients for cosmetics.
Epinal is revolutionising the detection and prevention of narcotic-impaired behaviour for safer roads, flights and workplaces. Utilising AI and novel biotechnology that mimics natural sensory mechanisms, it’s developing a handheld breathalyser that generates rapid results with extreme sensitivity and selectivity.
GenomeKey is transforming how healthcare clinicians diagnose and treat infections like sepsis to improve patient outcomes. Using cutting-edge machine learning and DNA sequencing, the company is developing a next-generation diagnostic device to identify bacterial genomes and determine their antimicrobial susceptibility directly from patient blood in just a few hours, rather than days. This enables clinicians to prescribe the right antibiotics for patients with much more efficiency and accuracy, reducing costs, minimising unnecessary antibiotic use and ultimately saving millions of lives from the world’s leading cause of death.